Sorry guys, just manage to hoop around and get it here.Writing this because the feel the amount of knowledge contribute by more informed people like pharmacist or doctor or researcher isn't around before and even after the PI-88. I maybe wrong as I have only read a few post on first page, some guru may have expressed his/her view. What I think PI-88 is a failure is totally expected, Heparanese and anti-angiogenesis, dual mechanism sound like a big plus, but really nothing more than just equivalent as 2 drugs use together, same effect. Remember last time screening for drug candidate pipeline, I skip this, do not even bother to read the share price. Why? Because the main mechanism of treating cancer is anti-angiogenesis, and I think any slightly educated in health care personnel will tell (after knowing the trial end point) you instantly the risk of failure is way to high, really hard to reach statistically significant, both PFS and OS. I think a lot of commentator on PGL bought in because of Medigen share performance in Taiwan, and do rough calculation without even bothering to read medical journal. In fact Medigen share price is overly inflated, even now, because biotech company is still new in Taiwan, mom and dad investors is much more clueless than most of us, and they bought in massively following the biotech hype and shoot Medigen company value similar to those who have product in produce company. Also Taiwan was broadcasting Medigen potential, gave the passing rate as high as 80% (had a nice laugh on their naive).
PGL Price at posting:
28.0¢ Sentiment: None Disclosure: Not Held
